The ten most commonly asked questions about sildenafil (Viagra)

Cardiol Rev. 1999 Jul-Aug;7(4):173-5. doi: 10.1097/00045415-199907000-00008.
No abstract available

MeSH terms

  • Cardiotonic Agents / pharmacology*
  • Cardiotonic Agents / therapeutic use
  • Cardiovascular Diseases / complications
  • Cardiovascular Diseases / drug therapy
  • Drug Interactions
  • Erectile Dysfunction / complications
  • Erectile Dysfunction / drug therapy
  • Half-Life
  • Humans
  • Hypotension / chemically induced
  • Male
  • Patient Education as Topic
  • Phosphodiesterase Inhibitors / pharmacology*
  • Phosphodiesterase Inhibitors / therapeutic use
  • Piperazines / pharmacology*
  • Piperazines / therapeutic use
  • Purines
  • Risk Assessment
  • Sildenafil Citrate
  • Sulfones
  • Vasodilator Agents / pharmacology*
  • Vasodilator Agents / therapeutic use

Substances

  • Cardiotonic Agents
  • Phosphodiesterase Inhibitors
  • Piperazines
  • Purines
  • Sulfones
  • Vasodilator Agents
  • Sildenafil Citrate